Teosyal® PureSense Redensity 2 is a professional-grade dermal filler designed to improve the appearance of tear troughs, under-eye hollows, and fine periorbital lines. Its unique formulation blends hyaluronic acid with a targeted nutrient complex and lidocaine for comfortable, precise treatment of sensitive areas. Suitable for trained medical professionals experienced in periocular injections, Redensity 2 supports natural-looking rejuvenation with long-lasting hydration and tissue support. This product is intended for clinicians seeking reliable correction for specific signs of ageing and volume loss in the thin skin around the eyes.
Pricing is available to registered aesthetic professionals only.
Sign in to view pricesTeosyal® PureSense Redensity 2 is a CE-marked, injectable hyaluronic acid (HA) dermal filler specifically formulated for use in delicate facial regions such as the periorbital area and tear troughs. Developed by Teoxane Laboratories (Switzerland), Redensity 2 combines cross-linked and non-cross-linked HA at 15 mg/ml with an advanced nutrient complex of 8 amino acids, 3 antioxidants, 2 minerals, and vitamin B6 to support tissue health and dermal function. All formulations contain lidocaine 0.3 % to enhance patient comfort during injection. Redensity 2’s viscoelastic gel is tailored for superficial to deep dermal placement where fine lines, under-eye hollows, and mild periorbital dark circles persist, delivering temporary structural support and hydration that typically lasts up to 9–12 months.
In clinical category and mechanism, Teosyal® PureSense Redensity 2 is similar to tear trough-specific hyaluronic acid fillers like Restylane® Differences and Belotero® Balance / Soft. All of these products provide temporary dermal volumisation and hydration by integrating HA into tissue planes with tailored viscoelastic properties for fine-line and contour correction. Redensity 2’s unique nutrient complex is designed for delicate zones and may offer supplementary antioxidative and amino-acid support not present in simple HA gels. As with most under-eye fillers, the depth of injection and product choice should align with anatomical requirements to minimise the risk of oedema or Tyndall effect. Duration of effect for these products generally ranges from 6–12 months, depending on filler cross-linking, gel characteristics, and individual patient factors. This comparison is provided for clinical orientation only and does not imply interchangeability.
Tear troughs (infraorbital hollows)
Periorbital under-eye region
Fine superficial wrinkles around the eye area
Mild under-eye dark circles with volume loss
Treatment areas per distributor product info (clinical use by trained professionals)
Direct injection parameters not publicly published in full IFU — the following reflects manufacturer indications where available; if not specified by IFU, noted as such.
Injection depth: Superficial to deep dermis or supra-periosteal plane in tear trough area
Injection technique: Microinjections by qualified medical professionals only
Needle gauge provided: 30 G × ½″ sterile needles included in packaging
Volume per site: Not provided by manufacturer in public product data
Frequency / sessions: Not provided by manufacturer in public product data
Professional use: Administered only by trained medical personnel under aseptic conditions
Some practitioners report supra-periosteal placement in tear troughs as a widely adopted method; this is not part of official manufacturer IFU.
Hyaluronic Acid (HA): 15 mg/ml (cross-linked + non-cross-linked)
Lidocaine Hydrochloride: 0.3 % for injection comfort
Amino acids: Glycine, Lysine, Threonine, Proline, Isoleucine, Leucine, Valine, Arginine
Antioxidants: Glutathione, N-acetyl-L-cysteine, Alpha-lipoic acid
Minerals: Zinc, Copper
Vitamin: B6 (Pyridoxine)
Packaging: 2 × 1 ml prefilled syringes, plus 2–4 × 30 G × ½″ needles and traceability labels
Shelf life: Not provided by manufacturer public documents
Longevity: Effects generally last up to 9–12 months, subject to patient factors
Contraindicated in patients with hypersensitivity to any component, including HA or lidocaine
Avoid in areas of active skin inflammation, infection, or compromised tissue
Not intended for deep malar bags or severe tear trough depressions
Requires professional assessment; injection risks include temporary swelling, bruising, redness, or tenderness
Follow full contraindications in the official IFU.
CE-marked Class III medical device (EU MDR) — meeting regulatory standards for safety and performance
Regulatory classification not specified in public documentation; verify on product pack or official IFU
FAQ
1. What is Teosyal® PureSense Redensity 2?
Teosyal® PureSense Redensity 2 is a professional hyaluronic acid dermal filler designed for treating under-eye hollows, fine lines, and mild dark circles. It combines HA with an advanced nutrient complex to support tissue hydration and structure in delicate periorbital areas. It includes lidocaine to reduce injection discomfort during procedures performed by trained professionals.
2. How does it work?
This filler works by physically restoring volume and hydrating the dermis via HA, which binds water within tissues. The added amino acids, antioxidants, minerals, and vitamin B6 contribute to microenvironment support but do not alter the mechanical volume-restoring function of HA.
3. How long do results last?
Clinical data from distributors and product literature indicate effects usually persist up to 9–12 months, though this varies with metabolism, technique, and patient lifestyle factors.
4. Is it safe?
When administered by trained clinicians following aseptic technique, Redensity 2 is generally safe. Common, usually transient events include swelling, bruising, redness, or tenderness at the injection site. Contraindications include active infection or hypersensitivity to any component.
5. How does it compare to other under-eye fillers?
Like other under-eye fillers (e.g., Restylane®) it provides temporary volume support. Its nutrient complex aims to support delicate tissue environments, but injection depth and practitioner expertise remain key determinants of outcomes. This is not medical advice; injector consultation is essential.
Let’s talk on WhatsApp